Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence

Journal:

Nature Communications

Published:

2025-11-25

DOI:

10.1038/s41467-025-65462-z

Affiliations:

18

Authors:

66

Go to article

Institutions	Authors	Share
The University of Texas MD Anderson Cancer Center, United States of America (USA)	63.000000 63.000000 63.000000 63.000000 63.000000 63.000000 63.000000	0.95
Baylor College of Medicine (BCM), United States of America (USA)	2.000000	0.03
University of Texas Graduate School of Biomedical Sciences (GSBS), United States of America (USA)	1.000000	0.02

Interested in Oncology and Carcinogenesis?